These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22446020)

  • 1. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
    Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
    Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
    Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
    Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
    Saridaki Z; Saegart X; De Vriendt V; Hatzidaki D; Palmans S; De Smedt L; De Hertogh G; Tejpar S
    Br J Cancer; 2015 Sep; 113(6):914-20. PubMed ID: 26325103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
    Nagasaka T; Sasamoto H; Notohara K; Cullings HM; Takeda M; Kimura K; Kambara T; MacPhee DG; Young J; Leggett BA; Jass JR; Tanaka N; Matsubara N
    J Clin Oncol; 2004 Nov; 22(22):4584-94. PubMed ID: 15542810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.
    Mariani P; Lae M; Degeorges A; Cacheux W; Lappartient E; Margogne A; Pierga JY; Girre V; Mignot L; Falcou MC; Salmon RJ; Delattre O; De Cremoux P
    Anticancer Res; 2010 Oct; 30(10):4229-35. PubMed ID: 21036746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
    Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
    Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
    Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
    Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
    Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
    Oliveira C; Velho S; Moutinho C; Ferreira A; Preto A; Domingo E; Capelinha AF; Duval A; Hamelin R; Machado JC; Schwartz S; Carneiro F; Seruca R
    Oncogene; 2007 Jan; 26(1):158-63. PubMed ID: 16953233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
    Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
    Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
    Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
    Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.
    Matos P; Oliveira C; Velho S; Gonçalves V; da Costa LT; Moyer MP; Seruca R; Jordan P
    Gastroenterology; 2008 Sep; 135(3):899-906. PubMed ID: 18602919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.
    Kang S; Kim HS; Seo SS; Park SY; Sidransky D; Dong SM
    Gynecol Oncol; 2007 Jun; 105(3):662-6. PubMed ID: 17360030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
    Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
    Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.